Clinical TrialJun 16, 2026, 07:41 AM
Clearmind Medicine Completes Dosing for Part A of Phase I/II Trial
AI Summary
Clearmind Medicine Inc. announced the successful completion of dosing for all 24 participants in Part A of its ongoing FDA-regulated Phase I/II clinical trial. The trial is evaluating CMND-100, a proprietary drug candidate, for the treatment of Alcohol Use Disorder (AUD). Interim results from the first three cohorts have indicated a strong safety profile, which is encouraging as the program advances under FDA oversight.
Key Highlights
- Clearmind Medicine completed dosing for all 24 participants in Part A of its Phase I/II clinical trial.
- The trial evaluates CMND-100 for the treatment of Alcohol Use Disorder (AUD).
- Participants were treated with escalating dose levels of CMND-100.
- Interim results from the first three cohorts showed a strong safety profile.
- The trial is being conducted under FDA oversight (IND).
- Clinical sites include Yale School of Medicine and Johns Hopkins University School of Medicine.
Price Impact
More from CMND